Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on rociletinib (CO-1686) in previously treated EGFR-mutant NSCLC; study phases 1/2 terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• rociletinib (rociletinib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-01-06